Top

Published in:

Open Access 01-09-2019 | Nausea | Original Article

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients

Authors: Giuseppe Badalamenti, Lorena Incorvaia, Carlo Messina, Emmanuela Musso, Alessandra Casarin, Maria Rita Ricciardi, Ida De Luca, Viviana Bazan, Antonio Russo

Published in: Supportive Care in Cancer | Issue 9/2019

Abstract

Purpose

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK₁ receptor antagonist (NK₁-RA), a 5-HT₃ receptor antagonist (5HT₃-RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK₁-RA, netupitant, and second-generation 5HT₃-RA, palonosetron. So far, no data has been published in literature about the efficacy of a single dose of NEPA in MD-CT.

Methods

We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medication) during the overall phase (0–120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2 and 3.

Results

The primary endpoint was reached in 88.9% of patients. Cycles 2 and 3 overall CR rates were 88.9% and 82.4%, respectively. The antiemetic regimen was well tolerated.

Conclusions

This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-chemotherapy.

Annunziata MA, Muzzatti B, Mella S, Bidoli E (2013) Fatigue, quality of life, and mood states during chemotherapy in Italian cancer patients. Tumori 99(1):e28–e33. https://doi.org/10.1700/1248.13808. CrossRefPubMed

Lorusso D, Bria E, Costantini A, Di Maio M, Rosti G, Mancuso A (2017) Patients’ perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life – an Italian survey. Eur J Cancer Care 26(2). https://doi.org/10.1111/ecc.12618

Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356–1367. https://doi.org/10.1056/NEJMra1515442 CrossRef

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261. https://doi.org/10.1200/JCO.2017.74.4789 CrossRef

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27 Suppl 5:v119-v133. https://doi.org/10.1093/annonc/mdw270.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M (2017) NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Cancer Netw 15(7):883–893. https://doi.org/10.6004/jnccn.2017.0117 CrossRef

Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H (2015) Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Cancer Med 4(3):333–341. https://doi.org/10.1002/cam4.373 CrossRefPubMed

Lorusso V (2016) Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron. Ther Clin Risk Manag 12:917–925. https://doi.org/10.2147/TCRM.S89215 CrossRefPubMedPubMedCentral

Aapro M, Molassiotis A, Dicato M, Pelae I, Rodriguez-Lescure A, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992. https://doi.org/10.1093/annonc/mds021 CrossRefPubMed

10.

Clark-Snow R, Affronti ML, Rittenberg CN (2018) Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 26(2):557–564. https://doi.org/10.1007/s00520-017-3866-6 CrossRefPubMed

11.

Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Annal Oncol 26(6):1081–1090. https://doi.org/10.1093/annonc/mdv138 CrossRef

12.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL (2017) Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 83(10):2148–2162. https://doi.org/10.1111/bcp.13322 CrossRefPubMedPubMedCentral

13.

Emend EPAR (European Public Assessment Report). Available at EMA website: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000527/WC500026534.pdf . Last access 03-April-2018.

14.

Varubi Medical Review, APPLICATION NUMBER: 206500Orig1s000. Available at FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206500Orig1s000MedR.pdf. Last access 13 Feb 2018.

15.

Akynzeo EPAR (European Public Assessment Report). Available at EMA web site: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/003728/WC500188434.pdf. Last access 03 April 2018.

16.

Schwartzberg L, Oprean C, Cardona-Huerta S, Rizzi G, Rossi G, Palmas M, Karthaus M, Aapro M (2013) No evidence of increased cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed-dose combination of netupitant and palonosetron. Blood 122:2949

17.

Aapro M, Jordan K, Palmas M, Clerici G, Rizzi G, Giorgino R (2016) No signals of increased toxicity after concomitant administration of NEPA with etoposide or docetaxel: pooled safety data analysis from 4 pivotal studies. Support Care Cancer 24(Suppl 1):S1–S249

18.

Bošnjak SM, Gralla RJ, Schwartzberg L (2017) Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK 1) receptor antagonists. Support Care Cancer 25(5):1661–1671. https://doi.org/10.1007/s00520-017-3585-z CrossRefPubMedPubMedCentral

19.

Séjourné A, Noal S, Boone M, Bihan C, Sassier M, Andrejak M, Chauffert B (2014) Two cases of fatal encephalopathy related to ifosfamide: an adverse role of aprepitant. Case Rep Oncol 7(3):669–672. https://doi.org/10.1159/000368184 CrossRefPubMedPubMedCentral

20.

Badalamenti G, Incorvaia L, Provenzano S, Bronte G, Leto G, Fulfaro F, Maltese G (2013) Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. Anticancer Res 33(2):679–684PubMed

21.

Celio L, Bonizzoni E, De Braud F, Agustoni F, Aapro M (2016) Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. Support Care Cancer 24(3):1025–1034. https://doi.org/10.1007/s00520-015-2871-x CrossRefPubMed

Title: One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
Authors: Giuseppe Badalamenti
Lorena Incorvaia
Carlo Messina
Emmanuela Musso
Alessandra Casarin
Maria Rita Ricciardi
Ida De Luca
Viviana Bazan
Antonio Russo
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Nausea
Vomiting
Sarcoma
Cytostatic Therapy
Dexamethasone
Published in: Supportive Care in Cancer / Issue 9/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-4645-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2019

Correction to: Reliability and validity of the Pittsburgh Sleep Quality Index in breast cancer patients

Respectful encounters from healthcare professionals and return to work among 9032 long-term sick-listed due to cancer or due to other diagnoses: results from a Swedish population-based survey

Ten-year experience of the multidisciplinary Osteoncology Center

Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study

Web-based videoconferencing for rural palliative care consultation with elderly patients at home

Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer